Private Placement

Silver One Resources (SLVRF) increased its private placement to $6,016,600 due to oversubscription, offering 21,487,857 units at $0.28 each, comprising one common share and a half-warrant. Warrants allow purchase of a share at $0.40 within three years. Proceeds will fund exploration/drilling and working capital. The offering is subject to TSX Venture Exchange approval and a four-month resale restriction. Silver One focuses on silver project development, including the Candelaria Mine in Nevada.

Defence Therapeutics (DTCFF) announced a non-brokered private placement to raise up to $1.2 million by offering debenture units priced at $1,000 each. Each unit includes an 8% convertible debenture (convertible at $0.60 per share) maturing in two years and 1,666 common share purchase warrants (exercisable at $0.75 per share for two years). Interest will be paid annually in cash or shares at the company’s discretion. Securities are subject to a four-month hold. The offering aims to fund the company’s antibody-drug conjugate (ADC) programs.

Discovery Energy Metals (DEMCF) closed a $1 million non-brokered private placement, issuing 10 million units at $0.10 each, comprising one common share and a transferable warrant. Warrants are exercisable at $0.15 per share for 24 months. Proceeds will fund working capital and property exploration. Issued securities are subject to a four-month statutory hold. The placement creates immediate shareholder dilution, with potential for further dilution upon warrant exercise.

Cambricon, a Chinese AI chip company, has received approval from the Shanghai Stock Exchange for a RMB 4 billion private placement. The funds will be used for AI chip and software platform development, particularly for large-scale AI models, and to supplement working capital. Cambricon’s Q1 2025 revenue surged by 4230.22% year-on-year, with net profit also significantly increasing. The company focuses on cloud, edge products, and IP licensing, aiming to build a comprehensive AI ecosystem.

bioAffinity Technologies (BIAF, BIAFW) secured financing through securities purchase agreements with investors, involving the sale of Series B Convertible Preferred Stock and warrants to purchase common stock in a private placement. They also reached a warrant exercise agreement, generating $253,000. These transactions aim to raise approximately $1.2 million for working capital and general corporate purposes, supporting the development and commercialization of their CyPath® Lung test, a non-invasive early lung cancer detection method with reported 92% sensitivity. WallachBeth Capital LLC acted as placement agent.

Ligand Pharmaceuticals (LGND) priced $400M convertible senior notes due 2030 in a private placement. The notes have a 0.75% interest rate and an initial conversion price of $194.79 per share, a 32.5% premium. Ligand expects $386.9M net proceeds, using $39.9M for hedge transactions, $15M to repurchase shares, and the rest for corporate purposes. The notes can be converted under certain conditions, and Ligand may redeem them after October 2028 if its stock price reaches 130% of the conversion price.

Revive Therapeutics (RVVTF) closed the first tranche of its private placement, raising $60,900 by issuing 2.9 million units at $0.021 each. It also settled $67,400 in debt by issuing 3.2 million units at the same price. Each unit includes a share and a warrant exercisable at $0.05 for 36 months. The proceeds will fund working capital and payables. Securities are subject to a hold period expiring December 9, 2025. The offering included 100,000 compensation options to an investment dealer.

SenesTech, Inc. (SNES), a biotech company specializing in fertility control for pest management, announced the closing of a warrant exercise generating $6.3 million. The company issued new short-term warrants priced at $0.125, potentially yielding an additional $11.5 million if fully exercised. SenesTech intends to use the net proceeds for working capital and general corporate initiatives. Their flagship product, ContraPest®, is a registered contraceptive for rats, aiming for humane and ecologically-sound pest control.

ETHZilla (formerly 180 Life Sciences) closed a $425 million private placement to advance its Ethereum treasury strategy. The company plans to rapidly increase its ETH holdings and execute a differentiated yield generation program in partnership with Electric Capital and with guidance from a new DeFi Council. ETHZilla aims to become a benchmark for on-chain treasury management, offering investors exposure to the Ethereum network. The capital will also support existing iGaming operations and IP monetization. The executive team and board have been expanded with crypto and capital markets expertise.

Legend Power Systems (LPSIF) received TSX Venture Exchange approval to extend the expiry date of 12,861,553 common share purchase warrants, originally issued in July and August 2023, from 2025 to July 31, 2026, and August 22, 2026, respectively. The exercise price remains at $0.25. Legend Power provides solutions like SmartGATE to enhance building energy efficiency, reduce costs and emissions, and improve asset management. The warrant extension gives holders more time to exercise their rights, but potential future dilution exists.